The Thymectomy Decision in MG

Written by Margaret Anne Rockwood | Last updated March 13, 2026
Medically reviewed by Nizar Souayah, MD

 

Thymic abnormalities, including thymic hyperplasia or thymoma (a slow-growing tumor composed of neoplastic thymic epithelial cells and non-neoplastic T lymphocytes) are common in MG.

The thymus plays a central role in immune system education and tolerance. Under normal circumstances, thymic epithelial cells facilitate positive and negative selection of developing T lymphocytes, ensuring that autoreactive T cells are eliminated before entering peripheral circulation.

In many patients with MG—especially those who are acetylcholine receptor positive (AChR+)—this normal process of central tolerance becomes dysregulated. The thymus frequently develops lymphoid follicular hyperplasia, characterized by ectopic germinal centers that resemble secondary lymphoid organs. These structures contain dense aggregates of B cells, follicular dendritic cells, and autoreactive CD4+ T helper cells. 

This abnormal thymic microenvironment supports sustained autoreactive immune activation. Within these thymic germinal centers:

• Autoreactive CD4+ T cells become activated.
• B cells undergo affinity maturation and clonal expansion.
• Anti-AChR autoantibodies are generated locally.
• Long-lived plasma cells develop and contribute to sustained antibody production.

Thus, in AChR-positive MG the thymus functions as an important site of autoimmune amplification and immune dysregulation—though it is not the sole source of pathogenic antibodies, as autoreactive B cells and plasma cells also reside in peripheral lymphoid tissues.

Thymectomy can reduce the burden of autoreactive immune activity and improve disease control over time. The randomized MGTX trial (Wolfe et al., 2016) demonstrated that at three years, thymectomy, combined with prednisone, resulted in significantly lower time-weighted Quantitative Myasthenia Gravis (QMG) scores (6.15 vs. 8.99, P<0.001) and lower corticosteroid requirements (32 mg vs. 54 mg alternate-day dosing, P<0.001) compared with prednisone alone.

At five years of follow-up (Wolfe et al., 2019), these benefits persisted, with a time-weighted mean QMG score approximately 3.87 points lower in the thymectomy group.

Who is a candidate?

Surgical removal of the thymus gland is beneficial in many patients. It may significantly improve long-term remission rates, but careful consideration is made of the patient subtype, comorbidities, age, and whether or not they have a thymoma.

The best candidates for successful thymectomy have:

• Early generalized AChR-positive MG
• A thymoma. Regardless of antibody type, thymectomy is ALWAYS indicated, for oncologic reasons as well as MG control
• Stable respiratory function
• Access to minimally invasive surgery, performed by an experienced thoracic surgeon at a surgery center

Thymectomy is not generally recommended in other populations:

• MuSK-Positive MG
  Thymic hyperplasia or thymoma is uncommon in MuSK-positive MG. Unlike AChR-positive disease, MuSK MG is mediated by IgG4 antibodies that directly block the agrin–LRP4–MuSK signaling pathway at the neuromuscular junction, rather than producing complement-mediated postsynaptic injury.Crucially, MuSK-positive MG typically lacks the thymic germinal center pathology that characterizes AChR-positive disease. The autoimmune process in MuSK MG is driven primarily by peripheral B-cell populations rather than by an abnormal thymic microenvironment. For these reasons, thymectomy has not demonstrated consistent clinical benefit in MuSK-positive MG.

• Ocular MG (AChR-Positive, Eyes Only)
  The role of thymectomy in purely ocular MG remains controversial. Many patients with isolated ocular symptoms respond well to pharmacologic therapy alone. However, thymectomy may be considered in selected individuals when medical therapy fails or when clinical and neurophysiological findings suggest a high likelihood of generalization.Younger patients with early disease and high AChR antibody titers may derive greater benefit. Recent observational data (2025) suggest complete stable remission rates of approximately 23% when thymectomy is performed during the ocular stage compared with approximately 11% when thymectomy is performed after generalization.

Benefits of Thymectomy for a Hyperactive Thymus

• Many patients experience long-term improvement in muscle strength after surgery.
• Over time, some patients are able to reduce the need for azathioprine by more than 50% (17% vs. 48% with steroids and other immunosuppressants), thereby lowering exposure to their side effects.
• Some patients, particularly younger adults with generalized MG, can achieve pharmacologic remission (minimal or no symptoms without drugs) several years after surgery.
• The benefit may increase over time, sometimes taking months to years to fully manifest, but leading to more stable disease over the long term.
• Some studies show fewer disease exacerbations and myasthenic crises after thymectomy, especially in AChR+ generalized MG. Thymectomy reduced hospitalizations for MG exacerbations by more than 50% (9% vs. 37%) in AChR+ generalized MG.

Benefits of Thymectomy for Patients with Thymomas

A thymoma is suspected through CT or MRI findings of a discrete anterior mediastinal mass. Removal is always indicated unless the patient is a poor surgical candidate due to severe comorbidities or prohibitive operative risk. The surgery’s chief benefits include: 

• Oncologic control: Thymectomy is the primary treatment for thymoma, providing excellent survival and local control, especially in early stages.
• Tumor removal: Prevents local compression and spread to the thoracic cavity
• MG symptom improvement: In thymoma-associated MG, meaningful clinical benefit often develops gradually over 6–24 months. Approximately 34% achieve complete stable remission and 38% achieve pharmacologic remission over the months and years following thymectomy.
• Combined benefit: Addresses both the malignancy and the autoimmune disease simultaneously

Considerations Prior to a Surgical Decision

Perioperative risks

The risk level depends heavily on how the surgery is done (open vs. minimally invasive) and MG severity at the time of surgery. Ideally, surgery is done when MG is well-controlled or, in higher-risk patients, often after preoperative IVIG or plasmapheresis. However, routine use of preventive IVIG in well-controlled patients is not recommended.

Common surgical risks (all approaches)

• Pain, bleeding, infection
• Pneumonia or atelectasis
• Blood clots (DVT/PE)
• Scarring

MG-specific anesthesia risks

MG patients are more sensitive to neuromuscular-blocking agents:

• Risk of post-op respiratory weakness
• Risk of prolonged ventilation or reintubation
• Higher risk if bulbar or respiratory MG is active

Surgical Success Rates

• Across all thymectomies for MG, approximately 8-20% of patients reached complete stable remission at 5 years, and up to 67% at 10 years in some cohorts. Pharmacologic remission (minimal or no symptoms without drugs) occurs in approximately 39-48% of patients.
• Clinical improvement after thymectomy typically occurs gradually over months to years rather than immediately.
• While surgical risks exist, serious adverse events are relatively uncommon with modern minimally invasive techniques.
• Age and disease duration influence outcomes. Younger patients (under 60–65) and those with early-stage generalized MG tend to benefit most.

Short- and medium-term risks

• Some patients experience transient symptom worsening before clinical improvement emerges. Note: Thymectomy does not replace pharmacologic therapy immediately.
• Risk of perioperative myasthenic crisis (generally <10% with modern perioperative management)
• No guarantee of benefit. Approximately 8–20% achieve complete stable remission off all immunotherapy at five years.
• The thymus is permanently removed. Although the long-term immunologic consequences in adults appear small, the procedure is irreversible.
• Myasthenic crisis, highest in:

• • Severe generalized MG
  • Bulbar/respiratory involvement
  • Poorly controlled disease
  • Strong history of prior myasthenic crisis
  • Vital capacity of <80%
  • Disease duration of <3 months

This is the most feared complication, but it is now uncommon with proper preparation.

Approach matters

Approach	Typical risks	References
Open sternotomy	More pain, longer recovery, higher infection risk, higher perioperative complication rates	[Y]
VATS / robotic	Lower complication rate, shorter hospital stay, fewer perioperative complications in non-thymomatous MG	[Z]

Modern minimally invasive approaches have much lower morbidity than older open surgeries.

Long-term downsides and uncertainties

There is no guarantee of benefit, even in ideal candidates.

• Most patients (82-84%) show some improvement(CHECK THIS WITHIN AChR+ pop).
• Only ~8-20% achieve complete stable remission and pharmacologic withdrawal at 5 years and up to 67% at 10 years.
• Approximately 39-48% achieve pharmacologic remission, while others improve but still need medications.
• A minority see little change.

Thymus removal is permanent

The thymus plays a role in immune regulation, especially earlier in life. Potential long-term considerations include a slightly increased risk of some infections and certain autoimmune diseases. In adults, these risks appear small, but not zero.

Rare Surgical Complications

• Phrenic nerve injury, leading to diaphragm weakness
• Recurrent laryngeal nerve injury, leading to hoarseness
• Chronic chest wall pain (uncommon, more with sternotomy)

Who is at higher risk for complications?

Patients with complications and poorer outcomes include those with:

• Poorly controlled MG
• Active bulbar or respiratory symptoms
• Older age
• Significant lung disease
• Open surgical approach

Who tends to tolerate thymectomy best?

Patients with the best outcomes in the short- and long-term include those with:

• Early generalized AChR-positive MG
• Stable respiratory function
• Minimally invasive surgery
• Experienced MG + thoracic surgery center

A Disease-Modifying Therapy, Not a Cure

Thymectomy is not usually curative for myasthenia gravis. Despite the significant outcomes reported, MG is a systemic autoimmune disease, so most patients continue to have some level of autoimmunity.

While the thymus is an important driver of the autoimmune response (especially in AChR+ MG), other immune cells outside the thymus — including B cells and T cells in the periphery — continue to produce autoantibodies even after the thymus is removed.

Additionally, the beneficial effects of thymectomy take months to years to be fully realized, and outcomes vary depending on factors like age, disease duration, antibody type, and the presence of thymoma.

In thymoma-associated MG, the positive effect on MG symptoms is more unpredictable than in non-thymomatous early-onset thymic hyperplastic MG. However, thymectomy is still indicated for oncologic reasons (tumor removal and prevention of local spread) and neurologic benefits in thymoma-associated MG can be robust.

The Bottom Line

Thymectomy is not a “quick fix.” It represents a long-term disease-modifying strategy that provides:

• Meaningful benefit in appropriately selected patients
• Real but generally manageable surgical risks
• A delayed but often durable clinical payoff

For many patients with early generalized AChR-positive myasthenia gravis, the long-term benefits of thymectomy outweigh the risks—when expectations are realistic and care is delivered by experienced multidisciplinary teams.

References

1. Myasthenia gravis. Gilhus NE. (2016). New England Journal of Medicine, 375(26), 2570–2581.
2. Myasthenia gravis: a comprehensive review of immune dysregulation and etiological mechanisms. Berrih-Aknin S, Le Panse R. (2014). Journal of Autoimmunity, 52, 90–100.
3. Thymic remodeling associated with hyperplasia in myasthenia gravis. Le Panse R, et al. (2010). Autoimmunity Reviews, 9(6), 370–375.
4. Randomized trial of thymectomy in myasthenia gravis. Wolfe GI, et al. (2016). New England Journal of Medicine, 375(6), 511–522.
5. Long-term effect of thymectomy plus prednisone versus prednisone alone in non-thymomatous myasthenia gravis (2-year extension of the MGTX trial). Wolfe GI, et al. (2019). Lancet Neurology, 18(3), 259–268.
6. International consensus guidance for management of myasthenia gravis. Sanders DB, et al. (2016). Neurology, 87(4), 419–425.
7. International consensus guidance update for management of myasthenia gravis. Narayanaswami P, et al. (2021). Neurology, 96(3), 114–122.
8. Pathogenic mechanisms of MuSK myasthenia gravis. Huijbers MG, et al. (2013). Annals of the New York Academy of Sciences, 1275, 41–46.
9. International consensus guidance for management of myasthenia gravis. Sanders DB, et al. (2016). Neurology, 87(4), 419–425.
10. Therapeutic options in ocular myasthenia gravis. Evoli A, et al. (2000). Neurology, 55(7), 1062–1067.
11. Development of generalized disease at 2 years in patients with ocular myasthenia gravis. Kupersmith MJ, Latkany R, Homel P. (2003). Archives of Neurology, 60(2), 243–248.
12. Incidence of thymoma in myasthenia gravis: a systematic review. Mao ZF, et al. (2015). Journal of Clinical Neurology, 11(3), 232–238.
13. Clinical value of the WHO classification system of thymoma. Detterbeck FC. (2010). Annals of Thoracic Surgery, 89(2), S730–S738.
14. Therapy for thymic epithelial tumors: a clinical study of 1,320 patients. Kondo K, Monden Y. (2003). Annals of Thoracic Surgery, 76(3), 878–884.
15. Myasthenia gravis. Gilhus NE. (2016). New England Journal of Medicine, 375(26), 2570–2581.
16. Assessment of the risks of a myasthenic crisis after thymectomy in patients with myasthenia gravis: a systematic review and meta-analysis of 25 studies. Geng, Y., Zhang, H., Wang, Y. 2020. Medicine.
17. Robot-assisted thoracoscopic surgery versus transsternal thymectomy for early-stage thymoma: a propensity score matching analysis. Ye, B. et al. (2014). Surg Endosc.